LAPIX plans to submit a third IND for LPX-TI641 in the first quarter of 2025 with the dermatology division at the US-FDA.

Rheumatoid arthritis is the most common inflammatory joint disorder, affecting over 60,000 people in Austria alone, with ...

That is the philosophy I carry into my ministry. Come as you are. Inform us, help us understand better, and you will want to ...